DexCom, Inc. , a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
Dexcom stock last closed at $68.57, down 0.23% from the previous day, and has decreased 48.77% in one year. It has underperformed other stocks in the Medical Devices industry by 0.31 percentage points. Dexcom stock is currently +19.21% from its 52-week low of $57.52, and -50.75% from its 52-week high of $139.24.
At the moment, there are 390.77M DXCM shares outstanding. The market capitalization of DXCM is $26.80B. In the past 24 hours, 3.7M DXCM shares were traded.
You will need an online brokerage account to access the NASDAQ market and buy DXCM stock.
We believe that eToro is the best brokerage. eToro gives you:
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've selected your brokerage, it's time to fill out some personal information so you are able to invest in DXCM stock today.
Now that you have created your account on stock apps to use, your next step is to transfer the money for your investment:
Check out the video below to see the process of transferring funds into your new brokerage account.
Once you have selected the best place to buy Dexcom stock, it's crucial to evaluate their stock prior to buying, so you truly wrap your head around the risk as well as the upside.
WallStreetZen was designed to help everyday investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on DXCM's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge DXCM's intrinsic value.
Using relative valuations metrics:
You can do additional valuation analysis on DXCM's stock here.
Out of 13 Wall Street analysts who give recommendations on DXCM, the consensus analyst rating on Dexcom is a Strong Buy
Please note that analyst forecasts are not recommendations, nor are they investment advice.
Jeff Johnson, a top 15% analyst from Baird upgrades DXCM to a buy rating and raises their DXCM price target from $86.00 to $104.00, on Jan 16, 2025.
Larry Biegelsen, a top 13% analyst from Wells Fargo maintains DXCM with a strong buy rating and raises their DXCM price target from $90.00 to $94.00, on Dec 11, 2024.
Wells Fargo's Larry Biegelsen raised their price target on Dexcom (NASDAQ: DXCM) by 4.4% from $90 to $94 on 2024/12/11. The analyst maintained their Strong Buy rating on the stock.
A new recommendation for CGM use in adults with T2 diabetes, including those who are not on insulin, is included in the American Diabetes Association's 2025 Standards of Care in Diabetes guidelines, Biegelsen told investors.
However, the analyst argued that each person's situation, preference, and requirements should be considered when selecting the appropriate gadget.
Nevertheless, Biegelsen said that this is a good development for names in their portfolio, including Dexcom and Abbott Laboratories.
Lee Hambright, a top 29% analyst from Bernstein maintains DXCM with a buy rating and raises their DXCM price target from $82.00 to $86.00, on Oct 25, 2024.
Jayson Bedford, a top 11% analyst from Raymond James maintains DXCM with a strong buy rating and lowers their DXCM price target from $115.00 to $99.00, on Oct 25, 2024.
Shagun Singh, a bottom 14% analyst from RBC Capital maintains DXCM with a buy rating and lowers their DXCM price target from $120.00 to $115.00, on Oct 25, 2024.
You can dig deeper into what analysts are forecasting on the Dexcom stock forecast page.
Last year, DXCM earnings were $576.20M. During the past 5 year, DXCM's earnings have increased by 39.34% per year. This was faster than the Medical Devices industry average of 10.26%.
Last year, DXCM revenue was $4.03B. In the past 5 year, DXCM's revenue has grown by 22.27% per year. This was faster than the Medical Devices industry average of 9.92%.
You can analyze DXCM's earnings and revenue performance here.
Over the last year, executives and large shareholders at DXCM have sold more shares than they have bought.
Bridgette P. Heller, Director of DXCM, was the latest DXCM insider to sell. They sold $24,756.16 worth of DXCM stock on Mar 17, 2025.
Research more about who owns DXCM shares here.
No, Dexcom doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other traders have to say.
You have two main options:
Hit the Open Trade button and eToro will execute your order.
If you want more info about investing in stocks on eToro, watch the how to video below:
Now that you own some DXCM shares, you'll want to stay up-to-date on your new investment.
Make a watchlist to get notified of important updates regarding your DXCM stock.
To reiterate, here are the 6 steps for buying Dexcom stock:
If you need a brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you want to monitor your investment in Dexcom, create a watchlist on WallStreetZen today.